Introduction：Basic information about CAS 499212-74-7|Pritumumab, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Pritumumab |
|---|
| CAS Number | 499212-74-7 | Molecular Weight | / |
|---|
| Density | / | Boiling Point | / |
|---|
| Molecular Formula | / | Melting Point | / |
|---|
| MSDS | / | Flash Point | / |
|---|
Names
Pritumumab BiologicalActivity
| Description | Pritumumab is a natural human IgG1kappa mAb originally isolated from a regional draining lymph node of a patient with cervical carcinoma. Pritumumab recognizes vimentin expressing on the cell surface of the malignant tumor. Pritumumab can be used for glioblastoma research[1][2]. |
|---|
| Related Catalog | Research Areas >>CancerSignaling Pathways >>Others >>Others |
|---|
| In Vivo | Pritumumab 在裸鼠中有效阻止肿瘤生长，但在SCID小鼠中无效[1]。 Pritumumab 只有在完整的细胞介导免疫存在的情况下，才能限制体内异种移植胶质瘤肿瘤的生长[1]。 |
|---|
| References | [1]. Santosh Kesari, et al. Pritumumab binding to glioma cells induces ADCC and inhibits tumor growth. ASCO Annual Meeting I. 2017. [2]. Hugwil AV. The meaning of the anti-cancer antibody CLN-IgG (Pritumumab) generated by human × human hybridoma technology against the cyto-skeletal protein, vimentin, in the course of the treatment of malignancy. Med Hypotheses. 2013 Sep;81(3):489-95. |
|---|
Chemical & Physical Properties
| No Any Chemical & Physical Properties |
